ArticleInternational journal of medical sciences2026
Synergistic Anticancer Effects of Lenvatinib Combined with N-butylidenephthalide in Human Colorectal Cancer Cells.
Article in International journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is one of the most prevalent and deadly gastrointestinal malignancies worldwide. Lenvatinib, a multi-tyrosine kinase inhibitor, has shown limited clinical benefit as a monotherapy for CRC. Therefore, combining lenvatinib with N-butylidenephthalide (BP), a known anticancer and adjuvant agent, has been explored to enhance therapeutic outcomes. This study investigates the effects of lenvatinib and BP, individually and in combination, on HCT15 and HCT116 CRC cell lines. Methods: Cell proliferation was assessed by MTT assay. Cell cycle distribution and apoptosis were measured with PI staining and annexin V-FITC staining, respectively, analyzed by flow cytometry. Reactive oxygen species (ROS) levels were determined using the DCFDA assay. Mitochondrial membrane potential (MMP) was evaluated with the JC-10 assay. Oxidative DNA damage was quantified by measuring 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels using an ELISA kit. Immunofluorescence staining was performed to evaluate γ-H2AX foci expression. Protein expression levels related to apoptosis and cell cycle regulation were analyzed by western blotting. Results: The combination of lenvatinib and BP exhibited synergistic cytotoxicity effect, promoting apoptosis by disrupting MMP in CRC cells. Additionally, this combination increased ROS accumulation, leading to oxidative DNA damage via 8-OHdG induction. Furthermore, the combination treatment induced G2/M phase cell cycle arrest by modulating the ATM-Chk2 signaling pathway. Conclusions: This study demonstrates that the combination of lenvatinib and BP represents a promising therapeutic strategy for CRC by enhancing apoptosis and cell cycle arrest through ROS-mediated DNA damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.